Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.
Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.
复制标题
DOI：
10.18632/oncotarget.13149
复制
发表时间：
2016-12-06
期刊：
影响因子：
--
通讯作者：
Ouadid-Ahidouch H
中科院分区：
文献类型：
--
作者：
Benzerdjeb N;Sevestre H;Ahidouch A;Ouadid-Ahidouch H
Orai3通道已成为恶性转化的重要参与者。事实上，它的表达在癌症中增加，并通过允许钙流入促进细胞增殖和存活。在这项研究中，与匹配的非肿瘤样本相比，Orai3在肺腺癌中过表达，并与肿瘤侵袭性相关。此外，在多因素分析中，其表达与雌激素受体α (ERα)表达和内脏胸膜浸润有关。此外，无论癌症分期如何，Orai3高表达肿瘤的总生存期（OS）中位数和无转移生存期（MFS）中位数均低于Orai3低表达肿瘤（OS为35.01个月比51.11个月，MFS为46.01个月比62.04个月）。综上所述，Orai3蛋白水平是肺腺癌独立的预后指标，是一种新的预后指标，可以帮助选择预后最差的患者在可切除期进行辅助化疗。
Orai3 channel has emerged as important player in malignant transformation. Indeed, its expression is increased in cancer and favors cell proliferation and survival by permitting calcium influx. In this study, Orai3 was overexpressed in lung adenocarcinoma as compared to their matched non-tumour samples and was associated with tumoural aggressiveness. Moreover, its expression was associated with estrogen receptor alpha (ERα) expression and visceral pleural invasion in multivariate analysis. Furthermore, both the overall survival (OS) median and the metastasis free survival (MFS) median of tumors with high Orai3 expression were lower than in low Orai3 expression regardless of cancer stage (35.01 months vs. 51.11 months for OS and 46.01 months vs. 62.04 months for MFS). In conclusion, Orai3 protein level constitutes an independent prognostic marker in lung adenocarcinoma, and a novel prognostic marker that could help selecting the patients with worst prognosis to be treated with adjuvant chemotherapy in resectable stage.